Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)

Dr. William B. Donnellan

Hematology Oncology | Hematology | Oncology
Tennessee Oncology PLLC
1208 Pointe Centre Dr, Suite 110, 
Chattanooga, TN 
 (224.1 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Tennessee Oncology PLLC
1208 Pointe Centre Dr, Suite 110, 
Chattanooga, TN 
 (224.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

William Donnellan is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Donnellan and is rated as an Experienced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Donnellan is currently accepting new patients.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Memorial Healthcare System, Inc
Tennova Health Care-Cleveland
Parkridge Medical Center
Erlanger Medical Center
Rhea Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Alliant Health
  •  UnitedHealthcare
  •  US Health and Life
  •  Oscar
View 1 More Insurance +

Locations

TENNESSEE ONCOLOGY PLLC
1208 Pointe Centre Dr, Suite 110, Chattanooga, TN 37421
Other Locations
TENNESSEE ONCOLOGY PLLC
2200 E 3rd St, Suite 100, Chattanooga, TN 37404
TENNESSEE ONCOLOGY PLLC
1032 Mccallie Ave, Suite 200, Chattanooga, TN 37403
TENNESSEE ONCOLOGY PLLC
605 Glenwood Dr, Suite 200, Chattanooga, TN 37404
TENNESSEE ONCOLOGY PLLC
1750 Cedar Ln, Suite 200, Tullahoma, TN 37388

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Enrollment Status: Recruiting
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: SEA-CD70
Study Phase: Phase 1
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study Assessing CPX-351 (Vyxeos™) With Quizartinib for the Treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML
A Phase II Study Assessing CPX-351 (Vyxeos™) With Quizartinib for the Treatment of Relapsed or Refractory FLT3-ITD Mutation-Positive AML
Enrollment Status: Terminated
Publish Date: December 05, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

14 Total Publications

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Journal: Hematological oncology
Published: January 31, 2024
Similar Doctors
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Robert M. Graham
Hematology Oncology | Hematology | Oncology
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Robert M. Graham
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

605 Glenwood Dr, Suite 200, 
Chattanooga, TN 
 (4.5 mi)
423-698-1844
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Graham is a Hematologist Oncology specialist and a Hematologist in Chattanooga, Tennessee. Dr. Graham and is rated as an Advanced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Childhood Iron Deficiency Anemia, Melanoma, Familial Pancreatic Cancer, and Paget Disease of the Breast. Dr. Graham is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile